Trials / Completed
CompletedNCT00141453
ORIENT: Olmesartan Reducing Incidence of End Stage Renal Disease in Diabetic Nephropathy Trial
CS-866DM Phase 3 Clinical Study: A Double-Blind Controlled Trial in Patients With Diabetic Nephropathy and Overt Proteinuria Secondary to Type 2 Diabetes Mellitus
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 577 (actual)
- Sponsor
- Daiichi Sankyo Co., Ltd. · Industry
- Sex
- All
- Age
- 30 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the effectiveness and safety of olmesartan versus placebo on the progression of diabetic renal disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | olmesartan medoxomil | Tablets 10, 20, or 40 mg |
| DRUG | Placebo Tablets | Matching placebo tablets |
Timeline
- Start date
- 2003-04-01
- Primary completion
- 2008-08-01
- Completion
- 2009-01-01
- First posted
- 2005-09-01
- Last updated
- 2011-05-10
- Results posted
- 2011-05-10
Locations
2 sites across 2 countries: China, Japan
Source: ClinicalTrials.gov record NCT00141453. Inclusion in this directory is not an endorsement.